Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -5.19 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 13.15 | — | 14.70 | 12.31 | 4.78 | 1.88 | 9.01 | 5.81 | 5.19 | 3.81 | 2.30 | — | 22.50 | 10.19 | 275.04 | 3.99 | 30.64 | 3.58 | 3.34 | 2.62 | 2.32 |
| — | — | +63.1% | +111.7% | -7.9% | -50.7% | +291.0% | — | -76.9% | -62.6% | -99.2% | — | -26.6% | +185.0% | +8132.7% | +52.3% | +1223.4% | +120.1% | +41.6% | +96.9% | +115.9% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -257.7% | — | -63.2% | -53.2% | -38.4% | -49.0% | -82.3% | -47.3% | -34.0% | -18.4% | -27.1% | -422.9% | -103.5% | -162.5% | -205.6% | -240.3% | -184.1% | -60.5% | -30.6% | -22.8% | -17.7% |
| — | — | +23.2% | -12.5% | -12.9% | -165.5% | -204.1% | +88.8% | +67.2% | +88.6% | +86.8% | -75.9% | +43.8% | -168.5% | -571.7% | -954.3% | -939.2% | -89.8% | -28.9% | -51.9% | +5.4% | |
| ROA | -135.9% | -66.9% | -27.2% | -31.3% | -26.0% | -29.5% | -38.9% | -28.6% | -22.2% | -12.6% | -14.5% | -25.1% | -26.7% | -33.1% | -35.4% | -41.8% | -45.3% | -28.1% | -17.2% | -16.8% | -16.1% |
| — | -126.9% | +30.2% | -9.4% | -17.2% | -134.8% | -167.6% | -14.0% | +16.8% | +62.1% | +59.0% | +40.1% | +41.1% | -18.1% | -106.1% | -149.6% | -182.3% | +1.7% | +20.5% | -20.5% | +6.0% | |
| ROIC | -244.5% | — | -119.8% | -81.3% | -193.4% | -270.1% | -76.3% | -36.7% | -24.3% | -27.8% | — | -3575.5% | -1033.3% | -1259.1% | -6701.6% | — | — | — | -3197.3% | -714.8% | -2271.4% |
| — | — | -57.1% | -121.4% | -694.7% | -870.2% | — | +99.0% | +97.6% | +97.8% | — | — | — | — | -109.6% | — | — | — | -481.7% | -415.5% | -2403.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.69 | — | 1.40 | 0.69 | 0.30 | 0.24 | 0.97 | 0.48 | 0.31 | 0.42 | 0.35 | — | 4.03 | 1.63 | 37.21 | 1.95 | 15.12 | 1.18 | 0.71 | 0.53 | 0.00 |
| — | — | +44.5% | +45.9% | -5.6% | -42.7% | +178.7% | — | -92.2% | -74.4% | -99.1% | — | -73.3% | +38.6% | +5136.2% | +264.9% | +570276.8% | +44028.6% | +16867.2% | +11694.9% | -69.5% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.39 | 0.95 | 2.62 | 4.39 | 5.14 | 6.64 | 3.51 | 5.46 | 6.78 | 4.56 | 3.29 | 0.82 | 5.36 | 7.65 | 0.90 | 1.27 | 3.03 | 5.81 | 9.40 | 9.80 | 11.29 |
| — | -85.6% | -25.1% | -19.5% | -24.1% | +45.5% | +6.5% | +568.9% | +26.4% | -40.4% | +266.6% | -35.5% | +77.0% | +31.7% | -90.4% | -87.1% | -73.2% | -36.0% | +8.5% | -22.2% | -13.3% | |
| Quick Ratio | 4.39 | 0.95 | 2.62 | 4.39 | 5.14 | 6.64 | 3.51 | 5.46 | 6.78 | 4.56 | 3.29 | 0.82 | 5.36 | 7.65 | 0.90 | 1.27 | 3.03 | 5.81 | 9.40 | 9.80 | 11.29 |
| — | -85.6% | -25.1% | -19.5% | -24.1% | +45.5% | +6.5% | +568.9% | +26.4% | -40.4% | +266.6% | -35.5% | +77.0% | +31.7% | -90.4% | -87.1% | -73.2% | -36.0% | +8.5% | -22.2% | -13.3% | |
| Interest Coverage | -65.73 | -268.92 | -36.11 | -57.41 | -74.21 | -65.59 | -68.34 | -61.74 | -33.19 | -9.52 | -6.99 | -5.96 | -8.10 | -10.57 | -14.69 | -19.53 | -26.19 | -24.91 | -20.21 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ACHV stock.
Achieve Life Sciences, Inc.'s current P/E is -5.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Achieve Life Sciences, Inc.'s business trajectory between earnings reports.